Celera Shares Fall as Earnings Miss Analyst Estimates | GenomeWeb

NEW YORK (GenomeWeb News) – Shares of Celera plummeted more than 20 percent today after the firm yesterday reported a loss for its fourth fiscal quarter and forecast lower revenue than analysts expected for 2009.

The company's shares were trading at $7.26 this afternoon, down 22 percent from yesterday's close of $9.34.

Celera yesterday reported revenues of $47.3 million for the three-month period ended Dec. 27, which was in line with analyst estimates.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: RNA-seq, ChIP-seq to determine metformin response; array-based approach to detect protozoa in blood; and more.

Fast Company takes a look at startups in the nutrigenomic space that aim to offer personalized diet advice.

In a glamorous event, the Breakthrough Foundation gave out more than $25 million in prizes to researchers.

Immunotherapy might treat cancer, but it also appears to come with a risk of a number of side effects, the New York Times reports.